Trial · NCT03625518
Mode of Induction in Fetal Growth Restriction and Its Affects on Fetal and Maternal Outcomes
NCT03625518, Early phase 1, Unknown, Tel-Aviv Sourasky Medical Center
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Mode of Induction in Fetal Growth Restriction and Its Affects on Fetal and Maternal Outcomes. Trials, record NCT03625518. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03625518
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Mode of Induction in Fetal Growth Restriction and Its Affects on Fetal and Maternal Outcomes
- NCT number
- NCT03625518
- Status
- Unknown
- Phases
- Early phase 1
- Enrollment
- 280 participants, estimated
- Lead sponsor
- Tel-Aviv Sourasky Medical Center
- Conditions
- Fetal Growth Retardation, Induction of Labor Affected Fetus / Newborn
- Interventions
- prostaglandins E2, intracervical balloon catheter combined with pitocin
- First posted
- 2018-08-10
- Last updated
- 2018-08-10
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | mode of delivery | immediate | vaginal delivery, instrumental delivery or cesarean delivery |
| Secondary | composite neonatal outcome | 3 months after delivery | apgar score at birth, umilical cord blood gases, neonatal intensive care unit hospitalization,Intra ventricular hemorrhage, periventricular leukomalacia, meconium aspiration syndrome, sepsis, convulsion, perinatal death, need for hypothermia treatment |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers7
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03625518
GET https://conductscience.org/api/trials/v1/NCT03625518/registered